Alternative splicing as a therapeutic target for human diseases

Methods Mol Biol. 2009:555:127-44. doi: 10.1007/978-1-60327-295-7_10.

Abstract

The majority of eukaryotic genes undergo alternative splicing, an evolutionarily conserved phenomenon, to generate functionally diverse protein isoforms from a single transcript. The fact that defective pre-mRNA splicing can generate non-functional and often toxic proteins with catastrophic effects, accurate removal of introns and joining of exons is vital for cell homeostasis. Thus, molecular tools that could either silence a disease-causing gene or regulate its expression in trans will find many therapeutic applications. Here we present two RNA-based approaches, namely RNAi and theophylline-responsive riboswitch that can regulate gene expression by loss-of-function and modulation of splicing, respectively. These strategies are likely to continue to play an integral role in studying gene function and drug discovery.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alternative Splicing / drug effects*
  • Aptamers, Nucleotide / metabolism
  • Aptamers, Nucleotide / pharmacology*
  • Cell Line, Tumor
  • Humans
  • RNA Interference*
  • RNA, Messenger / genetics
  • RNA, Small Interfering / genetics
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / metabolism
  • Theophylline / metabolism
  • Theophylline / pharmacology*
  • Transfection

Substances

  • Aptamers, Nucleotide
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Cell Surface
  • carcinoembryonic antigen binding protein, human
  • Theophylline